| NCT06682234 | Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease | NOT_YET_RECRUITING | PHASE2 | 2025-10 | 2025-10 | 2025-10 |
| NCT07128303 | Study of GS-5319 in Adults With Solid Tumors | RECRUITING | PHASE1 | 2025-08-28 | 2028-05 | 2028-05 |
| NCT07055451 | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV | RECRUITING | PHASE1 | 2025-08-12 | 2028-03 | 2028-03 |
| NCT07115368 | Study of GS-1219 in Participants With HIV-1 | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-08-11 | 2027-02 | 2026-12 |
| NCT07096193 | Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus | RECRUITING | PHASE1, PHASE2 | 2025-07-31 | 2029-02 | 2029-02 |
| NCT07047716 | Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) | RECRUITING | PHASE3 | 2025-07-25 | 2028-09 | 2028-09 |
| NCT07038447 | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases | ENROLLING_BY_INVITATION | PHASE1 | 2025-07-02 | 2029-07 | 2029-07 |
| NCT07001319 | Study of GS-3242 in Participants With HIV-1 | RECRUITING | PHASE1 | 2025-05-29 | 2027-02 | 2025-12 |
| NCT06902519 | Study of GS-0151 in Participants With Rheumatoid Arthritis | RECRUITING | PHASE1 | 2025-05-14 | 2027-01 | 2027-01 |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | RECRUITING | PHASE1, PHASE2 | 2025-04-30 | 2028-06 | 2028-06 |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | RECRUITING | PHASE3 | 2025-04-04 | 2029-10 | 2029-10 |
| NCT06749054 | Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children | RECRUITING | PHASE2 | 2025-03-26 | 2026-12 | 2026-06 |
| NCT06784973 | Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection | TERMINATED | PHASE2 | 2025-03-05 | 2025-04-16 | 2025-04-16 |
| NCT06727565 | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma. | RECRUITING | PHASE2 | 2025-02-18 | 2026-08 | 2026-08 |
| NCT06532656 | Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 | RECRUITING | PHASE2, PHASE3 | 2024-11-20 | 2028-08 | 2028-02 |
| NCT06613685 | Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2024-10-21 | 2030-08 | 2029-01 |
| NCT06585150 | Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection | TERMINATED | PHASE2 | 2024-10-14 | 2025-06-09 | 2025-05-08 |
| NCT06630286 | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-10-09 | 2030-08 | 2026-04 |
| NCT06630299 | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-10-08 | 2030-08 | 2026-04 |
| NCT06513312 | Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-10-07 | 2028-12 | 2026-05 |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | RECRUITING | PHASE3 | 2024-08-28 | 2029-06 | 2029-06 |
| NCT06562907 | Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) | RECRUITING | PHASE1 | 2024-08-28 | 2026-07 | 2026-07 |
| NCT06337032 | A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments | RECRUITING | PHASE4 | 2024-08-27 | 2034-03 | 2034-03 |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | RECRUITING | PHASE3 | 2024-08-23 | 2031-07 | 2028-07 |
| NCT06544733 | Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2024-08-20 | 2029-06 | 2028-01 |
| NCT06532565 | Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-07-26 | 2028-06 | 2028-06 |
| NCT06290934 | Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis | RECRUITING | PHASE2 | 2024-03-27 | 2027-07 | 2026-03 |
| NCT06333808 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-03-25 | 2029-12 | 2025-12 |
| NCT06253663 | Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-03-18 | 2027-07 | 2027-07 |
| NCT06167317 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-01-09 | 2028-09 | 2028-09 |
| NCT05996744 | Study of Obeldesivir in Children and Adolescents With COVID-19 | TERMINATED | PHASE2, PHASE3 | 2023-12-26 | 2024-02-23 | 2024-02-23 |
| NCT06101342 | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-12-13 | 2028-12 | 2028-12 |
| NCT06104306 | Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) | COMPLETED | PHASE4 | 2023-12-13 | 2025-04-23 | 2025-01-29 |
| NCT06029972 | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | RECRUITING | PHASE2 | 2023-12-05 | 2027-05 | 2026-04 |
| NCT06101329 | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-11-17 | 2028-01 | 2026-07 |
| NCT06079164 | Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-11-09 | 2028-01 | 2028-01 |
| NCT06082960 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-10-09 | 2026-11 | 2026-11 |
| NCT06031415 | Study of GS-0272 in Participants With Rheumatoid Arthritis | RECRUITING | PHASE1 | 2023-09-28 | 2026-03 | 2026-03 |
| NCT06051617 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | RECRUITING | PHASE3 | 2023-09-07 | 2030-08 | 2030-08 |
| NCT06060665 | Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-09-05 | 2026-06 | 2026-06 |
| NCT05729568 | A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-05-15 | 2029-12 | 2024-07-02 |
| NCT05840224 | Study of GS-4528 in Adults With Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-05-11 | 2025-12 | 2025-12 |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-05-08 | 2028-04 | 2028-04 |
| NCT05629208 | Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | RECRUITING | PHASE2 | 2023-04-17 | 2025-09 | 2025-08 |
| NCT05770895 | Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B | COMPLETED | PHASE1 | 2023-04-03 | 2025-01-15 | 2025-01-15 |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer | RECRUITING | PHASE2 | 2023-03-16 | 2029-09 | 2029-09 |
| NCT05760300 | A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function | COMPLETED | PHASE1 | 2023-03-15 | 2024-07-23 | 2024-07-18 |
| NCT05765344 | Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function | COMPLETED | PHASE1 | 2023-03-15 | 2025-01-13 | 2025-01-13 |
| NCT05676931 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-02-21 | 2027-12 | 2027-12 |
| NCT05605899 | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | RECRUITING | PHASE3 | 2023-02-10 | 2031-03 | 2031-03 |
| NCT05715528 | Study of Obeldesivir in Nonhospitalized Participants With COVID-19 | COMPLETED | PHASE3 | 2023-02-08 | 2024-01-23 | 2023-11-28 |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | RECRUITING | PHASE3 | 2022-12-12 | 2031-08 | 2027-06 |
| NCT05603143 | Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness | TERMINATED | PHASE3 | 2022-11-05 | 2023-11-07 | 2023-11-07 |
| NCT05537766 | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | TERMINATED | PHASE2 | 2022-11-01 | 2025-01-27 | 2025-01-27 |
| NCT05585307 | Study of Novel Antiretrovirals in Participants With HIV-1 | COMPLETED | PHASE1 | 2022-10-26 | 2024-03-18 | 2024-02-17 |
| NCT05502237 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | RECRUITING | PHASE3 | 2022-10-12 | 2028-06 | 2028-06 |
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-09-12 | 2030-10 | 2030-10 |
| NCT05458102 | Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels | TERMINATED | PHASE1 | 2022-08-19 | 2023-05-01 | 2023-05-01 |
| NCT05502341 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2022-08-16 | 2028-07 | 2025-09 |
| NCT05459571 | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-08-09 | 2025-12 | 2025-12 |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-08-09 | 2026-12 | 2026-12 |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-07-25 | 2027-02 | 2027-02 |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-07-20 | 2028-07 | 2028-07 |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | TERMINATED | PHASE2 | 2022-07-08 | 2024-06-26 | 2024-06-26 |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia | TERMINATED | PHASE3 | 2022-07-07 | 2024-04-11 | 2024-04-11 |
| NCT05165771 | Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment | WITHDRAWN | PHASE2 | 2022-07 | 2023-03 | 2023-02 |
| NCT05281510 | Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women | COMPLETED | PHASE2 | 2022-06-09 | 2025-01-16 | 2025-01-16 |
| NCT05186974 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-05-30 | 2026-02 | 2026-02 |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | TERMINATED | PHASE2 | 2021-12-14 | 2024-10-08 | 2024-10-08 |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-11-17 | 2026-01 | 2023-11-29 |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | TERMINATED | PHASE2 | 2021-11-09 | 2024-04-25 | 2024-04-25 |
| NCT04989803 | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | RECRUITING | PHASE1 | 2021-10-27 | 2027-05 | 2027-05 |
| NCT05101096 | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-10-20 | 2026-05 | 2026-05 |
| NCT05119907 | Study of Sacituzumab Govitecan in Patients With Solid Tumor | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-10-12 | 2025-10 | 2025-10 |
| NCT05052996 | Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-10-05 | 2027-11 | 2023-12-19 |
| NCT04827576 | Study of Magrolimab in Patients With Solid Tumors | TERMINATED | PHASE2 | 2021-10-01 | 2024-10-01 | 2024-10-01 |
| NCT04950764 | An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) | COMPLETED | PHASE1 | 2021-09-17 | 2025-02-27 | 2025-02-24 |
| NCT05006794 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-09-15 | 2029-03 | 2029-03 |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma | TERMINATED | PHASE2 | 2021-09-07 | 2024-10-02 | 2024-10-02 |
| NCT04809623 | Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | TERMINATED | PHASE1 | 2021-09-01 | 2022-10-18 | 2022-10-18 |
| NCT04994509 | Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-08-30 | 2028-01 | 2024-05-27 |
| NCT05007782 | Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors | RECRUITING | PHASE1 | 2021-08-18 | 2028-12 | 2028-12 |
| NCT04891770 | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | COMPLETED | PHASE2 | 2021-08-14 | 2024-07-19 | 2024-01-23 |
| NCT04971785 | Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2021-08-09 | 2024-12-09 | 2024-11-12 |
| NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | TERMINATED | PHASE1 | 2021-07-19 | 2024-05-18 | 2024-05-18 |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | TERMINATED | PHASE3 | 2021-07-01 | 2024-03-25 | 2024-03-25 |
| NCT04827589 | Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria | WITHDRAWN | PHASE2 | 2021-07 | 2022-09 | 2022-04 |
| NCT04925752 | Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-06-28 | 2028-05 | 2024-08-21 |
| NCT04778410 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies | TERMINATED | PHASE2 | 2021-06-28 | 2024-03-04 | 2024-03-04 |
| NCT04880434 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | COMPLETED | PHASE2 | 2021-04-27 | 2025-06-17 | 2024-11-26 |
| NCT04620733 | RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) | COMPLETED | PHASE3 | 2021-04-21 | 2023-08-11 | 2023-08-11 |
| NCT04811040 | Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection | COMPLETED | PHASE1 | 2021-04-08 | 2023-10-26 | 2022-06-09 |
| NCT04617522 | Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | RECRUITING | PHASE1 | 2021-04-06 | 2026-12 | 2026-12 |
| NCT04745351 | Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) | TERMINATED | PHASE3 | 2021-03-31 | 2022-05-24 | 2022-04-20 |
| NCT04747470 | Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors | TERMINATED | PHASE1 | 2021-03-25 | 2022-11-07 | 2022-11-07 |
| NCT04527991 | Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | COMPLETED | PHASE3 | 2021-01-13 | 2025-07-04 | 2025-07-04 |
| NCT04483700 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy | WITHDRAWN | PHASE3 | 2020-12 | 2024-06 | 2022-10 |
| NCT04483687 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy | WITHDRAWN | PHASE3 | 2020-12 | 2024-09 | 2023-01 |
| NCT04639986 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-11-23 | 2025-12 | 2025-12 |
| NCT04502706 | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | TERMINATED | PHASE1 | 2020-11-17 | 2022-03-31 | 2022-03-31 |
| NCT04608344 | Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants | COMPLETED | PHASE1 | 2020-11-04 | 2021-01-13 | 2021-01-13 |
| NCT04454437 | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-10-23 | 2025-12 | 2021-08-06 |
| NCT04501952 | Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734ā¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting | TERMINATED | PHASE3 | 2020-09-18 | 2021-05-06 | 2021-05-06 |
| NCT04539262 | Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation | COMPLETED | PHASE1, PHASE2 | 2020-09-14 | 2021-03-22 | 2021-02-26 |
| NCT04313881 | Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) | TERMINATED | PHASE3 | 2020-09-09 | 2023-09-13 | 2023-09-13 |
| NCT04319198 | Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | COMPLETED | PHASE4 | 2020-08-04 | 2024-10-18 | 2024-10-18 |
| NCT04431453 | Study of Remdesivir in Participants Below 18 Years Old With COVID-19 | COMPLETED | PHASE2, PHASE3 | 2020-07-21 | 2023-02-10 | 2023-02-10 |
| NCT04467684 | Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406 | COMPLETED | PHASE1 | 2020-07-07 | 2021-06-06 | 2021-05-30 |
| NCT04314843 | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma | TERMINATED | PHASE1 | 2020-05-26 | 2022-07-27 | 2021-03-16 |
| NCT04292730 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734ā¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | COMPLETED | PHASE3 | 2020-03-15 | 2020-06-26 | 2020-04-29 |
| NCT04292899 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734ā¢) in Participants With Severe Coronavirus Disease (COVID-19) | COMPLETED | PHASE3 | 2020-03-06 | 2020-06-30 | 2020-04-09 |
| NCT04211909 | Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2020-01-03 | 2020-11-12 | 2020-11-12 |
| NCT04155749 | Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | PHASE1 | 2019-12-23 | 2026-06 | 2024-10-03 |
| NCT04130919 | Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis | TERMINATED | PHASE2 | 2019-12-20 | 2021-12-14 | 2021-02-25 |
| NCT04115748 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy | TERMINATED | PHASE3 | 2019-12-03 | 2021-05-11 | 2021-01-19 |
| NCT04143594 | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV | COMPLETED | PHASE2 | 2019-11-22 | 2023-09-19 | 2021-10-05 |
| NCT04150068 | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2019-11-21 | 2027-01 | 2020-10-05 |
| NCT04115839 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy | TERMINATED | PHASE3 | 2019-11-13 | 2021-03-18 | 2021-01-04 |
| NCT04024813 | A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC | TERMINATED | PHASE2 | 2019-11-12 | 2020-01-09 | 2020-01-09 |
| NCT04002401 | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | COMPLETED | PHASE2 | 2019-11-05 | 2023-01-30 | 2023-01-30 |
| NCT04060147 | Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis | TERMINATED | PHASE1 | 2019-10-17 | 2021-09-02 | 2021-09-02 |
| NCT04112303 | Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis | COMPLETED | PHASE3 | 2019-10-16 | 2021-06-25 | 2021-03-26 |
| NCT03964727 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-10-15 | 2025-09 | 2025-01-15 |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | TERMINATED | PHASE1 | 2019-10-10 | 2022-12-02 | 2022-12-02 |
| NCT04049617 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors | TERMINATED | PHASE1 | 2019-08-26 | 2021-03-30 | 2021-03-30 |
| NCT03987074 | Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2019-07-29 | 2020-07-13 | 2020-07-13 |
| NCT04026165 | Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease | COMPLETED | PHASE2 | 2019-07-24 | 2021-09-03 | 2021-09-03 |
| NCT03960645 | Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters | COMPLETED | PHASE1 | 2019-06-28 | 2022-08-18 | 2022-07-21 |
| NCT03954704 | Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors | TERMINATED | PHASE1 | 2019-06-03 | 2021-04-15 | 2020-10-27 |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents | WITHDRAWN | PHASE1 | 2019-06 | 2026-02 | 2021-02 |
| NCT03852433 | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | COMPLETED | PHASE2 | 2019-05-31 | 2022-09-28 | 2022-04-05 |
| NCT03901339 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | COMPLETED | PHASE3 | 2019-05-08 | 2023-10-20 | 2023-10-20 |
| NCT03912831 | Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers | TERMINATED | PHASE1 | 2019-04-30 | 2022-02-18 | 2022-02-18 |
| NCT03852719 | Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) | COMPLETED | PHASE3 | 2019-04-17 | 2024-08-08 | 2020-11-26 |
| NCT03890120 | Study of Cilofexor in Adults With Primary Sclerosing Cholangitis | TERMINATED | PHASE3 | 2019-03-27 | 2022-12-23 | 2022-11-10 |
| NCT03761056 | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma | COMPLETED | PHASE2 | 2019-01-29 | 2023-10-12 | 2023-10-12 |
| NCT03820258 | Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection | TERMINATED | PHASE2 | 2019-01-28 | 2020-02-19 | 2019-12-04 |
| NCT03739866 | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults | COMPLETED | PHASE1 | 2018-11-26 | 2020-06-15 | 2019-11-14 |
| NCT03704298 | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma | TERMINATED | PHASE1 | 2018-11-20 | 2022-12-15 | 2021-05-07 |
| NCT03624036 | Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | TERMINATED | PHASE1 | 2018-11-15 | 2022-11-18 | 2021-02-12 |
| NCT03602560 | ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | COMPLETED | PHASE3 | 2018-10-01 | 2020-02-16 | 2020-02-16 |
| NCT03615066 | Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment | COMPLETED | PHASE2 | 2018-08-28 | 2021-04-12 | 2019-12-12 |
| NCT03631732 | Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants | COMPLETED | PHASE3 | 2018-08-28 | 2020-08-19 | 2019-08-12 |
| NCT03547973 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | RECRUITING | PHASE2 | 2018-08-13 | 2030-06 | 2030-06 |
| NCT03547908 | Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults | COMPLETED | PHASE3 | 2018-05-30 | 2024-03-07 | 2022-02-25 |
| NCT03558139 | Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy | COMPLETED | PHASE1 | 2018-05-23 | 2020-12-03 | 2020-12-03 |
| NCT03551522 | A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) | TERMINATED | PHASE2 | 2018-04-30 | 2020-08-10 | 2019-05-08 |
| NCT03491553 | Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B | COMPLETED | PHASE2 | 2018-04-06 | 2020-08-10 | 2019-03-22 |
| NCT03417778 | Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function | COMPLETED | PHASE1 | 2018-04-03 | 2018-08-09 | 2018-08-09 |
| NCT03472326 | Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus | TERMINATED | PHASE2 | 2018-04-03 | 2019-12-09 | 2019-12-09 |
| NCT03449446 | Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2018-03-21 | 2019-11-19 | 2019-10-30 |
| NCT03405935 | Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ā„ 65 Years | COMPLETED | PHASE3 | 2018-03-01 | 2020-05-29 | 2018-11-20 |
| NCT03434353 | Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) | TERMINATED | PHASE2 | 2018-02-28 | 2021-01-26 | 2020-01-20 |
| NCT03391466 | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma | COMPLETED | PHASE3 | 2018-01-25 | 2024-11-25 | 2021-03-18 |
| NCT03139370 | Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | TERMINATED | PHASE1 | 2017-12-27 | 2023-06-04 | 2021-06-30 |
| NCT03301506 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | ACTIVE_NOT_RECRUITING | PHASE3 | 2017-12-12 | 2028-11 | 2028-11 |
| NCT03219164 | Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria | TERMINATED | PHASE3 | 2017-11-28 | 2021-09-23 | 2020-05-27 |
| NCT03369002 | Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects | COMPLETED | PHASE1 | 2017-11-27 | 2018-05-15 | 2018-05-15 |
| NCT02574455 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | COMPLETED | PHASE3 | 2017-11-07 | 2020-12-08 | 2020-03-30 |
| NCT03318861 | Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma | TERMINATED | PHASE1 | 2017-10-20 | 2022-09-16 | 2018-12-17 |
| NCT03285711 | Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) | COMPLETED | PHASE2 | 2017-10-06 | 2020-02-03 | 2019-05-03 |
| NCT03248479 | Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies | TERMINATED | PHASE1 | 2017-09-08 | 2023-09-05 | 2023-09-05 |
| NCT03207815 | Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis | TERMINATED | PHASE2 | 2017-07-26 | 2021-04-22 | 2020-12-29 |
| NCT03180619 | Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) | COMPLETED | PHASE2 | 2017-06-29 | 2020-09-04 | 2019-03-27 |
| NCT03036839 | Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease | COMPLETED | PHASE2 | 2017-06-27 | 2019-02-14 | 2018-11-22 |
| NCT03105336 | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | COMPLETED | PHASE2 | 2017-06-20 | 2024-12-05 | 2024-12-05 |
| NCT03110380 | Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed | COMPLETED | PHASE3 | 2017-06-12 | 2021-02-10 | 2018-12-04 |
| NCT03134222 | Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) | COMPLETED | PHASE2 | 2017-05-24 | 2019-12-18 | 2019-03-13 |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | TERMINATED | PHASE1 | 2017-05-19 | 2019-02-26 | 2019-02-26 |
| NCT03060447 | Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers | COMPLETED | PHASE1 | 2017-05-09 | 2020-02-13 | 2020-02-13 |
| NCT03100942 | Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome | COMPLETED | PHASE2 | 2017-05-01 | 2019-10-02 | 2019-01-10 |
| NCT03118843 | Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study | COMPLETED | PHASE3 | 2017-04-25 | 2018-03-19 | 2018-03-19 |
| NCT03046056 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) | COMPLETED | PHASE2 | 2017-04-11 | 2020-07-20 | 2020-07-20 |
| NCT03077412 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease | COMPLETED | PHASE2 | 2017-04-06 | 2021-02-17 | 2021-01-20 |
| NCT02983617 | Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE2 | 2017-04-06 | 2020-10-01 | 2019-02-20 |
| NCT03074331 | Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2017-03-23 | 2018-02-07 | 2018-02-07 |
| NCT03036852 | Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease | COMPLETED | PHASE2 | 2017-03-22 | 2018-11-07 | 2018-08-13 |
| NCT03053050 | Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | TERMINATED | PHASE3 | 2017-02-13 | 2019-06-19 | 2019-06-19 |
| NCT03053063 | Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | TERMINATED | PHASE3 | 2017-01-30 | 2019-05-06 | 2019-05-06 |
| NCT03022981 | Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection | COMPLETED | PHASE2 | 2017-01-26 | 2020-02-26 | 2019-11-19 |
| NCT02994056 | Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis | COMPLETED | PHASE2 | 2017-01-23 | 2018-12-12 | 2018-09-25 |
| NCT02983604 | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | TERMINATED | PHASE1, PHASE2 | 2017-01-10 | 2018-07-19 | 2018-07-19 |
| NCT02979613 | Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed | COMPLETED | PHASE3 | 2016-12-29 | 2020-01-30 | 2018-09-10 |
| NCT02996682 | Efficacy and Safety of Sofosbuvir/Velpatasvir Ā± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis | COMPLETED | PHASE3 | 2016-12-26 | 2018-05-08 | 2018-02-13 |
| NCT02862574 | Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis | TERMINATED | PHASE2 | 2016-12-15 | 2017-08-07 | 2017-06-26 |
| NCT02968563 | Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE2 | 2016-12-13 | 2021-01-14 | 2019-06-17 |
| NCT02943447 | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis | TERMINATED | PHASE2 | 2016-12-01 | 2019-09-04 | 2019-09-04 |
| NCT02943460 | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis | COMPLETED | PHASE2 | 2016-11-29 | 2020-05-18 | 2018-02-28 |
| NCT02955602 | Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) | COMPLETED | PHASE2 | 2016-11-28 | 2019-07-08 | 2018-09-07 |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | TERMINATED | PHASE1, PHASE2 | 2016-11-21 | 2024-03-25 | 2024-03-25 |
| NCT02959138 | Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function | COMPLETED | PHASE1 | 2016-11-21 | 2018-10-05 | 2018-10-05 |
| NCT02914522 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis | COMPLETED | PHASE3 | 2016-11-14 | 2020-03-31 | 2020-03-31 |
| NCT02759562 | Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis | TERMINATED | PHASE2 | 2016-11-04 | 2017-07-21 | 2017-07-06 |
| NCT02953782 | Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | COMPLETED | PHASE1, PHASE2 | 2016-11-02 | 2020-02-10 | 2020-02-10 |
| NCT02932150 | Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | ACTIVE_NOT_RECRUITING | PHASE2 | 2016-11 | 2029-10 | 2025-12 |
| NCT02854605 | Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2016-10-26 | 2018-01-09 | 2018-01-09 |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | COMPLETED | PHASE1, PHASE2 | 2016-09-29 | 2023-01-12 | 2023-01-12 |
| NCT02891408 | Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function | COMPLETED | PHASE1 | 2016-09-23 | 2019-05-13 | 2019-05-05 |
| NCT02881320 | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2016-09-21 | 2026-11 | 2025-03-24 |
| NCT02885181 | Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate | COMPLETED | PHASE2 | 2016-09-21 | 2017-09-20 | 2017-08-22 |
| NCT02862535 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | TERMINATED | PHASE1 | 2016-09-20 | 2019-10-25 | 2019-10-25 |
| NCT02862548 | Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant | COMPLETED | PHASE2 | 2016-09-16 | 2021-05-05 | 2018-02-08 |
| NCT02842086 | Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection | ACTIVE_NOT_RECRUITING | PHASE3 | 2016-09-02 | 2027-09 | 2019-01-31 |
| NCT02864381 | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | COMPLETED | PHASE2 | 2016-09-01 | 2019-08-23 | 2017-11-08 |
| NCT02854631 | Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) | COMPLETED | PHASE2 | 2016-09-01 | 2018-05-31 | 2018-02-16 |
| NCT02889796 | Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate | COMPLETED | PHASE3 | 2016-08-30 | 2019-06-20 | 2018-07-04 |
| NCT02868242 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy | COMPLETED | PHASE2 | 2016-08-28 | 2019-02-03 | 2018-11-12 |
| NCT02886728 | Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy | COMPLETED | PHASE3 | 2016-08-08 | 2019-05-08 | 2018-10-05 |
| NCT02856555 | Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis | COMPLETED | PHASE2 | 2016-08-08 | 2017-07-18 | 2017-07-18 |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | WITHDRAWN | PHASE2 | 2016-08 | 2016-08 | 2016-08 |
| NCT02781558 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis | COMPLETED | PHASE2 | 2016-07-29 | 2017-10-27 | 2017-10-06 |
| NCT02873936 | Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment | COMPLETED | PHASE3 | 2016-07-27 | 2018-06-26 | 2018-03-20 |
| NCT02781571 | Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant | COMPLETED | PHASE2 | 2016-07-27 | 2017-07-28 | 2017-07-28 |
| NCT02822794 | Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen | COMPLETED | PHASE3 | 2016-07-25 | 2017-08-25 | 2017-06-02 |
| NCT02808312 | Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function | COMPLETED | PHASE1 | 2016-07-13 | 2018-10-16 | 2018-10-16 |
| NCT02781584 | Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2016-06-13 | 2020-12-17 | 2020-12-17 |
| NCT02728206 | Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation | COMPLETED | PHASE2 | 2016-06-12 | 2018-01-16 | 2018-01-16 |
| NCT02701634 | Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) | TERMINATED | PHASE2 | 2016-05-27 | 2018-03-06 | 2017-12-19 |
| NCT02739360 | Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3KĪ“ Inhibitor, GS-9820 | TERMINATED | PHASE4 | 2016-05-04 | 2017-12-28 | 2017-12-28 |
| NCT02671500 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV | COMPLETED | PHASE3 | 2016-04-19 | 2018-03-27 | 2018-01-05 |
| NCT02738333 | Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection | COMPLETED | PHASE3 | 2016-04-12 | 2017-05-11 | 2017-02-14 |
| NCT02722837 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE3 | 2016-04-04 | 2017-09-13 | 2017-06-26 |
| NCT02707601 | Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment | COMPLETED | PHASE3 | 2016-04-01 | 2017-09-29 | 2017-09-14 |
| NCT02614066 | A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) | COMPLETED | PHASE1, PHASE2 | 2016-03-07 | 2023-11-03 | 2022-07-23 |
| NCT02652624 | Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women | COMPLETED | PHASE3 | 2016-02-19 | 2018-11-26 | 2017-10-09 |
| NCT02568683 | Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | TERMINATED | PHASE1, PHASE2 | 2016-02-11 | 2017-06-22 | 2016-10-03 |
| NCT02625480 | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2016-02-01 | 2026-02 | 2026-02 |
| NCT02626026 | Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA) | COMPLETED | PHASE1 | 2016-01-26 | 2016-09-01 | 2016-09-01 |
| NCT02654002 | Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics | COMPLETED | PHASE1 | 2016-01-20 | 2016-07-14 | 2016-07-14 |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | TERMINATED | PHASE3 | 2016-01-14 | 2022-09-27 | 2022-09-27 |
| NCT02534350 | Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection | COMPLETED | PHASE2 | 2015-12-31 | 2017-09-27 | 2017-02-20 |
| NCT02538614 | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia | TERMINATED | PHASE1 | 2015-12-29 | 2017-07-05 | 2017-07-05 |
| NCT02639338 | Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis | COMPLETED | PHASE3 | 2015-12-23 | 2017-01-02 | 2016-10-12 |
| NCT02639247 | Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor | COMPLETED | PHASE3 | 2015-12-23 | 2017-01-18 | 2016-10-05 |
| NCT02613871 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection | COMPLETED | PHASE3 | 2015-12-22 | 2018-11-07 | 2017-01-04 |
| NCT02616783 | Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ā„ 60 Years | COMPLETED | PHASE3 | 2015-12-22 | 2018-03-21 | 2018-02-21 |
| NCT02616029 | Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I | COMPLETED | PHASE3 | 2015-12-17 | 2019-07-11 | 2018-10-11 |
| NCT02600819 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis | COMPLETED | PHASE3 | 2015-12-14 | 2019-10-15 | 2017-09-29 |
| NCT02607228 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer | TERMINATED | PHASE1, PHASE2 | 2015-12-08 | 2019-09-03 | 2017-10-25 |
| NCT02603107 | Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults | COMPLETED | PHASE3 | 2015-11-20 | 2019-12-23 | 2017-05-15 |
| NCT02605954 | Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults | COMPLETED | PHASE3 | 2015-11-18 | 2018-01-24 | 2017-06-14 |
| NCT02521376 | Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function | COMPLETED | PHASE1 | 2015-11-16 | 2017-10-25 | 2017-10-25 |
| NCT02607800 | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy | COMPLETED | PHASE3 | 2015-11-16 | 2017-01-11 | 2016-10-10 |
| NCT02607930 | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2015-11-13 | 2021-07-02 | 2017-05-09 |
| NCT02607956 | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2015-11-11 | 2021-07-05 | 2017-05-12 |
| NCT02603120 | Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed | COMPLETED | PHASE3 | 2015-11-11 | 2019-10-23 | 2017-05-09 |
| NCT02600351 | Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies | TERMINATED | PHASE3 | 2015-11-11 | 2017-05-29 | 2017-03-21 |
| NCT02607735 | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy | COMPLETED | PHASE3 | 2015-11-11 | 2017-06-21 | 2016-10-10 |
| NCT02579382 | Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated | COMPLETED | PHASE2 | 2015-11-10 | 2019-05-03 | 2017-01-16 |
| NCT02601313 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) | COMPLETED | PHASE2 | 2015-11-09 | 2023-09-22 | 2023-09-22 |
| NCT02609048 | Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) | TERMINATED | PHASE2 | 2015-11-04 | 2016-07-01 | 2016-07-01 |
| NCT02678338 | CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies | COMPLETED | PHASE1 | 2015-11 | 2019-02 | 2018-11 |
| NCT02533427 | Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol | COMPLETED | PHASE1 | 2015-10-29 | 2016-03-18 | 2016-03-18 |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | COMPLETED | PHASE3 | 2015-10-13 | 2019-05-15 | 2019-05-15 |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | TERMINATED | PHASE2 | 2015-09-14 | 2016-05-03 | 2016-04-12 |
| NCT02457559 | Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies | COMPLETED | PHASE1 | 2015-09-10 | 2020-12-30 | 2020-12-30 |
| NCT02487030 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection | COMPLETED | PHASE3 | 2015-09-07 | 2017-02-04 | 2016-11-11 |
| NCT02520284 | Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis | TERMINATED | PHASE2, PHASE3 | 2015-09 | 2016-11 | 2016-09 |
| NCT02509624 | Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function | COMPLETED | PHASE1 | 2015-08-18 | 2015-12-15 | 2015-12-15 |
| NCT02876796 | Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects | COMPLETED | PHASE1 | 2015-08 | 2015-10 | 2015-09 |
| NCT02468557 | Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma | TERMINATED | PHASE1 | 2015-07-30 | 2016-04-27 | 2016-04-27 |
| NCT02536313 | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen | COMPLETED | PHASE2 | 2015-07-29 | 2016-06-28 | 2016-03-28 |
| NCT02365506 | Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome | COMPLETED | PHASE1 | 2015-07-20 | 2016-06-13 | 2016-05-13 |
| NCT02479880 | Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection | TERMINATED | PHASE4 | 2015-07-03 | 2018-04-11 | 2018-02-28 |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | TERMINATED | PHASE1, PHASE2 | 2015-07-01 | 2019-02-21 | 2018-09-04 |
| NCT02480712 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection | COMPLETED | PHASE3 | 2015-07-01 | 2016-06-22 | 2016-04-29 |
| NCT02469246 | Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC | COMPLETED | PHASE3 | 2015-06-29 | 2019-03-13 | 2017-12-11 |
| NCT02836249 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China) | COMPLETED | PHASE3 | 2015-06-19 | 2023-08-31 | 2017-03-21 |
| NCT02836236 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China) | COMPLETED | PHASE3 | 2015-06-19 | 2023-09-18 | 2017-04-05 |
| NCT02472886 | Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection | COMPLETED | PHASE3 | 2015-06-17 | 2016-06-30 | 2016-03-30 |
| NCT02457598 | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | TERMINATED | PHASE1 | 2015-06-16 | 2024-09-25 | 2024-09-25 |
| NCT02466516 | Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 | COMPLETED | PHASE2 | 2015-06-08 | 2016-10-11 | 2016-10-11 |
| NCT02436135 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease | TERMINATED | PHASE1 | 2015-06-05 | 2017-11-20 | 2017-11-20 |
| NCT02457611 | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection | COMPLETED | PHASE2 | 2015-06 | 2016-01 | 2016-01 |
| NCT02350569 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting | COMPLETED | PHASE2 | 2015-05-22 | 2016-04-22 | 2016-03-28 |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | TERMINATED | PHASE1, PHASE2 | 2015-05-06 | 2018-12-17 | 2018-11-16 |
| NCT02402452 | Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment | COMPLETED | PHASE1 | 2015-05-05 | 2015-09-28 | 2015-09-28 |
| NCT02441829 | Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function | COMPLETED | PHASE1 | 2015-05 | 2015-12 | 2015-12 |
| NCT02377336 | GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease | WITHDRAWN | PHASE2 | 2015-05 | 2016-08 | 2016-08 |
| NCT02405442 | Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease | TERMINATED | PHASE2 | 2015-04-30 | 2016-12-22 | 2016-11-30 |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | COMPLETED | PHASE1, PHASE2 | 2015-04-21 | 2023-07-27 | 2023-07-27 |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | TERMINATED | PHASE3 | 2015-04-21 | 2016-05-13 | 2016-05-13 |
| NCT02400307 | Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function | COMPLETED | PHASE1 | 2015-04-17 | 2015-07-13 | 2015-07-06 |
| NCT02413593 | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection | COMPLETED | PHASE2 | 2015-04 | 2016-01 | 2015-12 |
| NCT02472535 | Study to Evaluate the Effects of MBX-8025 in Patients With HoFH | COMPLETED | PHASE2 | 2015-04 | 2016-02 | 2016-02 |
| NCT02397707 | Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment | COMPLETED | PHASE1 | 2015-03-24 | 2016-03-04 | 2016-03-04 |
| NCT02397694 | Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE2 | 2015-03-23 | 2019-02-27 | 2015-11-30 |
| NCT02412098 | Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function | COMPLETED | PHASE1 | 2015-03-19 | 2016-04-22 | 2016-04-22 |
| NCT02392611 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | COMPLETED | PHASE1 | 2015-03-16 | 2017-10-11 | 2017-10-11 |
| NCT02301936 | Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease | COMPLETED | PHASE2 | 2015-03-02 | 2016-04-18 | 2016-04-18 |
| NCT02346721 | Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection | COMPLETED | PHASE3 | 2015-02-23 | 2016-06-15 | 2016-03-23 |
| NCT02378935 | Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection | COMPLETED | PHASE2 | 2015-02-17 | 2016-04-12 | 2016-02-01 |
| NCT02378961 | Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection | COMPLETED | PHASE2 | 2015-02-16 | 2016-01-26 | 2015-09-21 |
| NCT02291237 | Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy | TERMINATED | PHASE2, PHASE3 | 2015-02-05 | 2017-02-17 | 2017-01-20 |
| NCT02365532 | Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults | COMPLETED | PHASE1 | 2015-02 | 2015-05 | 2015-05 |
| NCT02254421 | Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract | COMPLETED | PHASE2 | 2015-01-31 | 2017-04-17 | 2017-04-17 |
| NCT02858401 | Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults | COMPLETED | PHASE1 | 2015-01-29 | 2019-02-14 | 2019-02-14 |
| NCT02345252 | Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) | COMPLETED | PHASE3 | 2015-01-26 | 2019-01-09 | 2016-06-22 |
| NCT02345226 | Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults | COMPLETED | PHASE3 | 2015-01-26 | 2019-01-02 | 2016-06-29 |
| NCT02254408 | Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract | COMPLETED | PHASE2 | 2015-01-23 | 2017-07-14 | 2017-07-14 |
| NCT02285114 | Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen | COMPLETED | PHASE2, PHASE3 | 2015-01-20 | 2024-12-11 | 2019-11-04 |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma | TERMINATED | PHASE1 | 2015-01 | 2015-08 | 2015-08 |
| NCT02296853 | Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment | COMPLETED | PHASE1 | 2014-12-22 | 2015-04-17 | 2015-04-17 |
| NCT02300558 | Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 | TERMINATED | PHASE3 | 2014-12-17 | 2017-02-15 | 2016-12-12 |
| NCT02246998 | Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults | COMPLETED | PHASE4 | 2014-12-15 | 2016-02-17 | 2016-01-20 |
| NCT02276612 | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents | COMPLETED | PHASE2, PHASE3 | 2014-12-03 | 2017-10-23 | 2016-11-10 |
| NCT02300103 | Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study | COMPLETED | PHASE2 | 2014-12-01 | 2016-09-15 | 2016-07-02 |
| NCT02249182 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection | COMPLETED | PHASE2 | 2014-11-05 | 2018-08-24 | 2018-06-15 |
| NCT02234141 | Selonsertib in Adults With Pulmonary Arterial Hypertension | COMPLETED | PHASE2 | 2014-11 | 2016-12 | 2016-04 |
| NCT02275065 | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants | COMPLETED | PHASE1 | 2014-10-24 | 2015-01-29 | 2015-01-23 |
| NCT02251717 | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection | COMPLETED | PHASE2 | 2014-10-14 | 2016-06-16 | 2016-03-24 |
| NCT02242045 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE1 | 2014-10-01 | 2017-10-17 | 2014-12-25 |
| NCT02104583 | Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator | COMPLETED | PHASE2 | 2014-09 | 2016-10 | 2016-09 |
| NCT02220998 | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection | COMPLETED | PHASE3 | 2014-09 | 2015-09 | 2015-07 |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | TERMINATED | PHASE2 | 2014-08-06 | 2016-05-17 | 2016-04-27 |
| NCT02202980 | Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection | COMPLETED | PHASE2 | 2014-08-04 | 2016-05-09 | 2016-03-16 |
| NCT02216409 | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | COMPLETED | PHASE1 | 2014-08 | 2018-12 | 2018-10 |
| NCT02219685 | Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection | COMPLETED | PHASE2 | 2014-08 | 2016-04 | 2015-08 |
| NCT02176876 | Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis | COMPLETED | PHASE1 | 2014-08 | 2015-06 | 2015-04 |
| NCT02252835 | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout | COMPLETED | PHASE2 | 2014-08 | 2014-12 | 2014-12 |
| NCT02209987 | Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults | COMPLETED | PHASE1 | 2014-08 | 2014-10 | 2014-10 |
| NCT02174276 | Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment | COMPLETED | PHASE2 | 2014-07-24 | 2018-05-30 | 2016-02-17 |
| NCT02175758 | Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection | COMPLETED | PHASE2 | 2014-07-07 | 2018-09-13 | 2018-06-21 |
| NCT01987453 | Ledipasvir/Sofosbuvir Fixed-Dose Combination Ā± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study | COMPLETED | PHASE2 | 2014-07 | 2015-11 | 2015-11 |
| NCT02201901 | Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis | COMPLETED | PHASE3 | 2014-07 | 2015-11 | 2015-08 |
| NCT02201953 | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection | COMPLETED | PHASE3 | 2014-07 | 2015-12 | 2015-09 |
| NCT02201940 | Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection | COMPLETED | PHASE3 | 2014-07 | 2015-09 | 2015-06 |
| NCT02226549 | Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis | COMPLETED | PHASE2 | 2014-07 | 2015-02 | 2015-02 |
| NCT02166047 | Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants | COMPLETED | PHASE2 | 2014-06-30 | 2016-10-20 | 2016-05-11 |
| NCT02185794 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE1 | 2014-06-13 | 2015-09-28 | 2014-12-22 |
| NCT02135614 | Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection | COMPLETED | PHASE2 | 2014-06-09 | 2017-04-12 | 2017-03-27 |
| NCT02177786 | Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease | COMPLETED | PHASE2 | 2014-06 | 2016-08 | 2016-07 |
| NCT02128542 | Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis | COMPLETED | PHASE4 | 2014-06 | 2015-06 | 2015-06 |
| NCT02121795 | Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF | COMPLETED | PHASE3 | 2014-05-06 | 2019-03-01 | 2015-08-12 |
| NCT02120300 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders | COMPLETED | PHASE2 | 2014-04 | 2015-08 | 2015-08 |
| NCT02077465 | Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE1 | 2014-03-11 | 2014-10-27 | 2014-10-27 |
| NCT02063997 | Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients | COMPLETED | PHASE2 | 2014-03 | 2015-01 | 2015-01 |
| NCT02074514 | Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection | COMPLETED | PHASE3 | 2014-03 | 2015-11 | 2015-09 |
| NCT02081079 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection | COMPLETED | PHASE2 | 2014-03 | 2015-02 | 2014-11 |
| NCT02071082 | Efficacy and Safety of E/C/F/TAF (GenvoyaĀ®) in HIV-1/Hepatitis B Co-infected Adults | COMPLETED | PHASE3 | 2014-02-25 | 2016-10-26 | 2015-01-23 |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | TERMINATED | PHASE3 | 2014-02-05 | 2016-06-16 | 2016-05-30 |
| NCT02073656 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection | COMPLETED | PHASE3 | 2014-02 | 2015-12 | 2014-11 |
| NCT02016924 | Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2014-01-16 | 2027-03 | 2025-06-13 |
| NCT02010255 | Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant | COMPLETED | PHASE2 | 2014-01 | 2015-08 | 2015-05 |
| NCT02002767 | Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment | COMPLETED | PHASE1 | 2013-12-16 | 2014-06-09 | 2014-06-09 |
| NCT02021656 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection | COMPLETED | PHASE3 | 2013-12-10 | 2017-09-29 | 2017-07-08 |
| NCT02021643 | Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection | COMPLETED | PHASE3 | 2013-12-10 | 2016-11-03 | 2016-08-12 |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | TERMINATED | PHASE1 | 2013-12 | 2015-03 | 2015-03 |
| NCT01956812 | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer | TERMINATED | PHASE3 | 2013-12 | 2016-11 | 2016-11 |
| NCT01967940 | Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults | COMPLETED | PHASE3 | 2013-10-25 | 2017-07-31 | 2015-05-21 |
| NCT01958281 | Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency | COMPLETED | PHASE2 | 2013-10-07 | 2017-10-19 | 2017-07-18 |
| NCT01965535 | Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination Ā± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection | COMPLETED | PHASE2 | 2013-10 | 2014-11 | 2014-08 |
| NCT01975675 | Efficacy and Safety of Sofosbuvir/Ledipasvir Ā± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection | COMPLETED | PHASE3 | 2013-10 | 2014-08 | 2014-06 |
| NCT01984294 | Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection | COMPLETED | PHASE2 | 2013-10 | 2014-07 | 2014-04 |
| NCT01962441 | SOF (SovaldiĀ®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection | COMPLETED | PHASE3 | 2013-09-24 | 2016-07-07 | 2015-01-07 |
| NCT01943799 | Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B | COMPLETED | PHASE2 | 2013-09-13 | 2015-03-03 | 2014-09-09 |
| NCT01940341 | Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen | COMPLETED | PHASE3 | 2013-09-12 | 2022-08-31 | 2015-09-30 |
| NCT01940471 | Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen | COMPLETED | PHASE3 | 2013-09-11 | 2022-10-13 | 2015-11-16 |
| NCT01968551 | Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults | COMPLETED | PHASE3 | 2013-09-03 | 2016-07-09 | 2015-07-21 |
| NCT01915472 | A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer | WITHDRAWN | PHASE2 | 2013-09 | 2015-08 | 2015-08 |
| NCT01938430 | Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant | COMPLETED | PHASE2 | 2013-09 | 2015-03 | 2015-01 |
| NCT01923311 | Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants | TERMINATED | PHASE2, PHASE3 | 2013-08-26 | 2017-11-03 | 2017-11-03 |
| NCT01924949 | Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection | COMPLETED | PHASE2 | 2013-07 | 2014-08 | 2014-05 |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | TERMINATED | PHASE2 | 2013-06-20 | 2016-12-22 | 2015-01 |
| NCT01909804 | Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection | COMPLETED | PHASE2 | 2013-06 | 2014-08 | 2014-05 |
| NCT01896193 | Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection | COMPLETED | PHASE3 | 2013-06 | 2014-06 | 2014-04 |
| NCT01854775 | Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children | COMPLETED | PHASE2, PHASE3 | 2013-05-06 | 2025-06-18 | 2020-05-11 |
| NCT01851330 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination Ā± Ribavirin for the Treatment of HCV (ION-3) | COMPLETED | PHASE3 | 2013-05 | 2014-03 | 2013-12 |
| NCT01849003 | Study of the Effect of GS-6615 in Subjects With LQT-3 | COMPLETED | PHASE1 | 2013-05 | 2014-11 | 2014-11 |
| NCT01840735 | Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF | COMPLETED | PHASE1 | 2013-05 | 2013-08 | 2013-07 |
| NCT01841489 | A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics | COMPLETED | PHASE1 | 2013-05 | 2013-10 | 2013-08 |
| NCT01847391 | A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects | COMPLETED | PHASE1 | 2013-05 | 2013-11 | 2013-11 |
| NCT01797419 | Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) | WITHDRAWN | PHASE1 | 2013-05 | 2013-08 | 2013-08 |
| NCT01826981 | Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection | COMPLETED | PHASE2 | 2013-04 | 2015-05 | 2015-03 |
| NCT01858766 | Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection | COMPLETED | PHASE2 | 2013-04 | 2014-08 | 2014-05 |
| NCT01843127 | A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes. | COMPLETED | PHASE1 | 2013-04 | 2013-09 | 2013-09 |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 | 2013-03-29 | 2019-04-23 | 2019-04-23 |
| NCT01831427 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis | COMPLETED | PHASE1 | 2013-03-28 | 2015-02-06 | 2015-01-05 |
| NCT01815736 | Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants | COMPLETED | PHASE3 | 2013-03-27 | 2020-04-01 | 2015-03-16 |
| NCT01818596 | Open-label Safety Study of E/C/F/TAF (GenvoyaĀ®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment | COMPLETED | PHASE3 | 2013-03-27 | 2018-07-18 | 2014-07-31 |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | TERMINATED | PHASE2 | 2013-03-14 | 2020-01-30 | 2017-09-14 |
| NCT01797445 | Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2013-03-12 | 2018-10-03 | 2014-09-19 |
| NCT01672853 | Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) | COMPLETED | PHASE2 | 2013-03-04 | 2016-08-24 | 2016-08-08 |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | TERMINATED | PHASE1 | 2013-03 | 2017-03 | 2017-03 |
| NCT01838590 | Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE3 | 2013-03 | 2014-08 | 2014-05 |
| NCT01817985 | A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment | COMPLETED | PHASE1 | 2013-03 | 2013-08 | 2013-08 |
| NCT01801293 | A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 | COMPLETED | PHASE1 | 2013-03 | 2013-04 | 2013-04 |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | TERMINATED | PHASE1, PHASE2 | 2013-02-12 | 2017-01-03 | 2017-01-03 |
| NCT01910636 | Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection | COMPLETED | PHASE3 | 2013-02 | 2014-06 | 2014-03 |
| NCT01808248 | Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3 | COMPLETED | PHASE2 | 2013-02 | 2013-12 | 2013-09 |
| NCT01769196 | Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) | TERMINATED | PHASE2 | 2013-01-31 | 2016-02-23 | 2016-02-23 |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | TERMINATED | PHASE3 | 2013-01-16 | 2016-05-18 | 2016-05-18 |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | TERMINATED | PHASE3 | 2013-01-02 | 2016-05-17 | 2016-05-17 |
| NCT01783678 | A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults | COMPLETED | PHASE3 | 2013-01 | 2014-07 | 2014-04 |
| NCT01768286 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination Ā± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection | COMPLETED | PHASE3 | 2013-01 | 2014-02 | 2013-11 |
| NCT01779505 | A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults | COMPLETED | PHASE1 | 2013-01 | 2013-08 | 2013-08 |
| NCT01780506 | Study to Evaluate the Safety and Efficacy of E/C/F/TAF (GenvoyaĀ®) Versus E/C/F/TDF (StribildĀ®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2012-12-26 | 2017-09-06 | 2014-08-26 |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | COMPLETED | PHASE1, PHASE2 | 2012-12-17 | 2020-08-13 | 2019-03-01 |
| NCT01651403 | Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection | ACTIVE_NOT_RECRUITING | PHASE3 | 2012-12-06 | 2027-07 | 2017-08-07 |
| NCT01721109 | Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents | COMPLETED | PHASE2, PHASE3 | 2012-12-06 | 2018-01-29 | 2015-10-22 |
| NCT01672866 | Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) | TERMINATED | PHASE2 | 2012-12-05 | 2016-12-29 | 2016-08-02 |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | TERMINATED | PHASE3 | 2012-12-04 | 2018-08-15 | 2018-08-15 |
| NCT01641822 | Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF | COMPLETED | PHASE3 | 2012-12 | 2015-01 | 2015-01 |
| NCT01740791 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection | COMPLETED | PHASE1 | 2012-11-06 | 2014-01-24 | 2013-03-15 |
| NCT01705847 | A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies | COMPLETED | PHASE1 | 2012-11 | 2016-05 | 2016-05 |
| NCT01756482 | Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) | COMPLETED | PHASE2 | 2012-11 | 2013-06 | 2013-06 |
| NCT01687270 | Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant | COMPLETED | PHASE2 | 2012-11 | 2014-08 | 2013-12 |
| NCT01672879 | Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH | TERMINATED | PHASE2 | 2012-10-29 | 2017-01-03 | 2016-09-26 |
| NCT01705574 | Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women | COMPLETED | PHASE3 | 2012-10-24 | 2018-09-06 | 2015-02-09 |
| NCT01759511 | Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) | TERMINATED | PHASE2 | 2012-10-18 | 2016-02-19 | 2016-02-19 |
| NCT01707472 | Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis | COMPLETED | PHASE2 | 2012-10-04 | 2014-10-17 | 2014-10-17 |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | TERMINATED | PHASE3 | 2012-10-03 | 2018-06-29 | 2018-05-21 |
| NCT01713283 | Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2 | 2012-10 | 2014-02 | 2013-11 |
| NCT01726517 | Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) Ā± Ribavirin in HCV Genotype 1 Subjects | COMPLETED | PHASE2 | 2012-10 | 2014-01 | 2013-07 |
| NCT01793649 | A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects | TERMINATED | PHASE1 | 2012-10 | 2013-06 | 2013-06 |
| NCT01701401 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV | COMPLETED | PHASE3 | 2012-09 | 2014-04 | 2014-03 |
| NCT01682720 | Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection | COMPLETED | PHASE3 | 2012-09 | 2014-01 | 2013-10 |
| NCT01659255 | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL | COMPLETED | PHASE1 | 2012-08-17 | 2016-01-11 | 2015-02-23 |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | TERMINATED | PHASE1, PHASE2 | 2012-08 | 2017-10 | 2016-11 |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | WITHDRAWN | PHASE2 | 2012-08 | 2015-12 | 2014-12 |
| NCT01687257 | Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation | COMPLETED | PHASE2 | 2012-07 | 2015-10 | 2015-01 |
| NCT01667731 | Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults | COMPLETED | PHASE3 | 2012-07 | 2014-02 | 2013-11 |
| NCT01675973 | A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine | TERMINATED | PHASE1 | 2012-07 | 2012-08 | 2012-08 |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | COMPLETED | PHASE3 | 2012-06-15 | 2019-06-10 | 2019-06-10 |
| NCT01625338 | Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies | COMPLETED | PHASE3 | 2012-06 | 2014-12 | 2014-10 |
| NCT01555164 | A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone | COMPLETED | PHASE3 | 2012-06 | 2013-10 | 2013-09 |
| NCT01604850 | Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) | COMPLETED | PHASE3 | 2012-06 | 2013-05 | 2013-02 |
| NCT01641640 | Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection | COMPLETED | PHASE3 | 2012-06 | 2013-04 | 2013-01 |
| NCT01565850 | D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults | COMPLETED | PHASE2 | 2012-04 | 2014-02 | 2013-01 |
| NCT01539512 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE3 | 2012-04 | 2014-04 | 2013-10 |
| NCT01590654 | A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection | COMPLETED | PHASE1 | 2012-04 | 2013-12 | 2013-11 |
| NCT01590641 | A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B | COMPLETED | PHASE1 | 2012-04 | 2013-10 | 2013-09 |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | WITHDRAWN | PHASE1 | 2012-03 | 2015-09 | 2015-06 |
| NCT01559844 | Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant | COMPLETED | PHASE2 | 2012-03 | 2014-10 | 2014-05 |
| NCT01565889 | Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. | COMPLETED | PHASE1, PHASE2 | 2012-03 | 2013-11 | 2013-08 |
| NCT01542788 | Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon | COMPLETED | PHASE3 | 2012-03 | 2013-02 | 2012-11 |
| NCT01671787 | A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B | COMPLETED | PHASE1 | 2012-03 | 2013-04 | 2013-04 |
| NCT01591668 | A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C | COMPLETED | PHASE1 | 2012-03 | 2012-12 | 2012-12 |
| NCT01546558 | Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg | COMPLETED | PHASE1 | 2012-02 | 2012-03 | 2012-03 |
| NCT01546597 | Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine | COMPLETED | PHASE1 | 2012-02 | 2012-03 | 2012-03 |
| NCT01522651 | Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation | COMPLETED | PHASE2 | 2012-01-24 | 2014-03-10 | 2014-03-10 |
| NCT01533259 | Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients | COMPLETED | PHASE3 | 2012-01 | 2013-07 | 2012-11 |
| NCT01494987 | Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus | COMPLETED | PHASE3 | 2012-01 | 2013-08 | 2013-08 |
| NCT01497899 | Safety and Efficacy of E/C/F/TAF (GenvoyaĀ®) Versus E/C/F/TDF (StribildĀ®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE2 | 2011-12-28 | 2016-08-22 | 2012-10-17 |
| NCT01479465 | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | TERMINATED | PHASE2 | 2011-12 | 2015-02 | 2014-10 |
| NCT01495702 | Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients | COMPLETED | PHASE3 | 2011-12 | 2014-12 | 2013-11 |
| NCT01404234 | Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways | COMPLETED | PHASE3 | 2011-12 | 2013-04 | 2013-04 |
| NCT01497366 | Phase 3 Study of Sofosbuvir and Ribavirin | COMPLETED | PHASE3 | 2011-12 | 2013-04 | 2013-01 |
| NCT01475838 | Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients | COMPLETED | PHASE3 | 2011-11 | 2014-12 | 2013-11 |
| NCT01472198 | A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma | COMPLETED | PHASE2 | 2011-11 | 2015-02 | 2013-10 |
| NCT01472185 | Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus | COMPLETED | PHASE3 | 2011-11 | 2013-10 | 2013-10 |
| NCT01452308 | Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis | COMPLETED | PHASE2 | 2011-11 | 2013-08 | 2013-01 |
| NCT01442038 | Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) | COMPLETED | PHASE3 | 2011-10 | 2015-02 | 2015-02 |
| NCT01440569 | Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults | COMPLETED | PHASE3 | 2011-09 | 2015-10 | 2012-08 |
| NCT01393106 | Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | COMPLETED | PHASE2 | 2011-09 | 2014-08 | 2014-08 |
| NCT01425359 | Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina | COMPLETED | PHASE4 | 2011-09 | 2012-10 | 2012-10 |
| NCT01435044 | Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection | COMPLETED | PHASE2 | 2011-09 | 2013-05 | 2013-04 |
| NCT01434498 | GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2 | 2011-09 | 2013-01 | 2013-01 |
| NCT01435226 | GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2 | 2011-09 | 2013-07 | 2013-01 |
| NCT01431898 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE1 | 2011-09 | 2012-05 | 2011-12 |
| NCT01416402 | Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients | COMPLETED | PHASE2 | 2011-08 | 2011-10 | 2011-10 |
| NCT01375049 | Aztreonam Lysine for Pseudomonas Infection Eradication Study | COMPLETED | PHASE2 | 2011-08 | 2013-05 | 2013-05 |
| NCT01384383 | GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-NaĆÆve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype | TERMINATED | PHASE2 | 2011-08 | 2013-06 | 2013-06 |
| NCT01356160 | GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus | COMPLETED | PHASE2 | 2011-07 | 2013-06 | 2013-06 |
| NCT01371578 | Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection | COMPLETED | PHASE2 | 2011-07 | 2013-03 | 2013-03 |
| NCT01497327 | Open-Label Hepatic Impairment Study | COMPLETED | PHASE1 | 2011-07 | 2012-01 | 2012-01 |
| NCT01369498 | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | COMPLETED | PHASE2 | 2011-06-30 | 2014-09-24 | 2014-06-05 |
| NCT01399008 | Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients | COMPLETED | PHASE2 | 2011-06 | 2012-02 | 2012-02 |
| NCT01363011 | Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment | COMPLETED | PHASE3 | 2011-05 | 2015-02 | 2013-01 |
| NCT01336686 | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout | COMPLETED | PHASE2 | 2011-05 | 2011-11 | 2011-11 |
| NCT01270698 | Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer | COMPLETED | PHASE1 | 2011-05 | 2014-12 | 2014-12 |
| NCT01353248 | GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection | COMPLETED | PHASE2 | 2011-05 | 2013-03 | 2012-10 |
| NCT01334203 | A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM) | WITHDRAWN | PHASE4 | 2011-05 | 2012-12 | 2012-10 |
| NCT01320943 | Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB | COMPLETED | PHASE4 | 2011-04-26 | 2016-08-23 | 2016-07-28 |
| NCT01277601 | Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon Ī±-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B | COMPLETED | PHASE4 | 2011-04 | 2015-07 | 2014-08 |
| NCT01259713 | Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia | COMPLETED | PHASE3 | 2011-04 | 2014-01 | 2013-12 |
| NCT01313624 | Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis | COMPLETED | PHASE3 | 2011-04 | 2013-06 | 2013-03 |
| NCT01314716 | Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis | COMPLETED | PHASE3 | 2011-04 | 2013-07 | 2013-04 |
| NCT01282424 | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | COMPLETED | PHASE2 | 2011-03-18 | 2018-05-16 | 2018-05-02 |
| NCT01329978 | Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 | COMPLETED | PHASE2 | 2011-03 | 2012-08 | 2012-08 |
| NCT01273402 | Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer | WITHDRAWN | PHASE1 | 2011-02 | 2018-08 | 2013-02 |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | COMPLETED | PHASE1, PHASE2 | 2011-02 | 2015-08 | 2015-08 |
| NCT01309243 | Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2011-02 | 2014-02 | 2012-09 |
| NCT01286740 | Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR | COMPLETED | PHASE2 | 2011-01 | 2012-03 | 2011-07 |
| NCT01316237 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment NaĆÆve Subjects With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE1 | 2011-01 | 2012-01 | 2011-10 |
| NCT01362231 | A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis | COMPLETED | PHASE1 | 2010-12 | 2012-12 | 2012-12 |
| NCT01260350 | Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-NaĆÆve Patients With HCV GT2 or GT3 | COMPLETED | PHASE2 | 2010-12 | 2013-12 | 2013-10 |
| NCT01252940 | Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF | COMPLETED | PHASE3 | 2010-11 | 2014-10 | 2012-01 |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | TERMINATED | PHASE2 | 2010-10 | 2016-06 | 2015-08 |
| NCT01271790 | A Study of Response-Guided Duration of Combination Therapy With GS-9451, PegasysĀ® and CopegusĀ® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | COMPLETED | PHASE2 | 2010-10 | 2013-09 | 2013-01 |
| NCT01225380 | A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, PegasysĀ® and CopegusĀ® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | COMPLETED | PHASE2 | 2010-10 | 2013-09 | 2013-01 |
| NCT01221272 | Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging | COMPLETED | PHASE4 | 2010-09 | 2012-09 | 2012-09 |
| NCT01188772 | Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients | COMPLETED | PHASE2 | 2010-08 | 2012-05 | 2011-04 |
| NCT01334567 | Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan | COMPLETED | PHASE2 | 2010-08 | 2013-12 | 2013-12 |
| NCT01193478 | A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | COMPLETED | PHASE1 | 2010-08 | 2011-12 | 2011-01 |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | TERMINATED | PHASE1, PHASE2 | 2010-07 | 2013-07 | 2013-07 |
| NCT01163721 | Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy | COMPLETED | PHASE2 | 2010-06 | 2010-11 | 2010-11 |
| NCT01323933 | First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors | COMPLETED | PHASE1 | 2010-06 | 2012-03 | 2012-03 |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | WITHDRAWN | PHASE1, PHASE2 | 2010-05 | 2017-03 | 2016-12 |
| NCT01108510 | Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2010-04 | 2015-04 | 2011-11 |
| NCT01106586 | Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2010-04 | 2014-09 | 2011-09 |
| NCT01163734 | Ranolazine in Diastolic Heart Failure | COMPLETED | PHASE2 | 2010-04 | 2011-02 | 2011-02 |
| NCT01088048 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | COMPLETED | PHASE1 | 2010-03-25 | 2015-04-28 | 2015-04-28 |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | TERMINATED | PHASE1, PHASE2 | 2010-03-22 | 2018-06-18 | 2018-06-18 |
| NCT01095796 | Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE3 | 2010-03 | 2014-09 | 2011-08 |
| NCT01059565 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection | COMPLETED | PHASE3 | 2010-02 | 2012-01 | 2011-09 |
| NCT01072695 | Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection | COMPLETED | PHASE2 | 2010-02 | 2012-01 | 2010-10 |
| NCT01054729 | Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment NaĆÆve GT 1 HCV Patients | COMPLETED | PHASE2 | 2010-01 | 2011-08 | 2010-04 |
| NCT01066611 | Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber | COMPLETED | PHASE1 | 2010-01 | 2010-04 | 2010-04 |
| NCT01025713 | A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF) | WITHDRAWN | PHASE1 | 2009-12 | 2010-04 | 2010-03 |
| NCT01035879 | Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes | COMPLETED | PHASE2 | 2009-12 | 2010-08 | 2010-08 |
| NCT00650949 | Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | TERMINATED | PHASE1, PHASE2 | 2009-11 | 2011-06 | 2011-06 |
| NCT00999531 | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers | COMPLETED | PHASE1 | 2009-10 | 2010-03 | 2010-02 |
| NCT00951522 | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers | COMPLETED | PHASE1 | 2009-09 | 2009-09 | 2009-09 |
| NCT00936715 | Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States | COMPLETED | PHASE2 | 2009-08 | 2015-11 | 2015-11 |
| NCT00879229 | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis | TERMINATED | PHASE3 | 2009-07 | 2011-02 | 2011-02 |
| NCT00892437 | Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE2 | 2009-05 | 2015-01 | 2009-12 |
| NCT00874796 | Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection | TERMINATED | PHASE2 | 2009-05 | 2010-07 | 2010-04 |
| NCT00869557 | Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | COMPLETED | PHASE2 | 2009-04 | 2013-09 | 2009-11 |
| NCT00907764 | Stress Echocardiography Study With Regadenoson | TERMINATED | PHASE2 | 2009-04 | 2010-04 | 2010-04 |
| NCT00836914 | Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber | COMPLETED | PHASE1 | 2009-02 | 2009-03 | 2009-03 |
| NCT00832572 | Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy | TERMINATED | PHASE4 | 2009-01 | 2009-06 | 2009-06 |
| NCT00832507 | Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) | TERMINATED | PHASE2 | 2009-01 | 2012-03 | 2011-10 |
| NCT00734162 | Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection | COMPLETED | PHASE3 | 2008-12 | 2015-12 | 2011-03 |
| NCT00814372 | Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin | TERMINATED | PHASE2 | 2008-12 | 2010-02 | 2010-02 |
| NCT00768300 | (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF | TERMINATED | PHASE3 | 2008-12 | 2011-02 | 2011-02 |
| NCT00805025 | Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis | COMPLETED | PHASE2 | 2008-12 | 2009-10 | 2009-10 |
| NCT00777920 | Study of Ambrisentan in Participants With Pulmonary Hypertension | COMPLETED | PHASE3 | 2008-11-17 | 2019-09-11 | 2019-09-11 |
| NCT00794586 | Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection | COMPLETED | PHASE2 | 2008-11 | 2010-03 | 2010-02 |
| NCT00800579 | Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers | COMPLETED | PHASE1 | 2008-11 | 2009-02 | 2009-02 |
| NCT00743795 | Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection | COMPLETED | PHASE2 | 2008-10 | 2013-09 | 2009-07 |
| NCT00772902 | ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial | COMPLETED | PHASE4 | 2008-10 | 2009-10 | 2009-09 |
| NCT00737568 | Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine | COMPLETED | PHASE3 | 2008-09 | 2015-02 | 2011-11 |
| NCT00740610 | Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2008-08 | 2009-09 | 2009-08 |
| NCT00603668 | Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL | COMPLETED | PHASE1, PHASE2 | 2008-08 | 2013-02 | 2013-01 |
| NCT00736190 | A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection | COMPLETED | PHASE4 | 2008-08 | 2010-07 | 2010-07 |
| NCT00757237 | Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa | COMPLETED | PHASE3 | 2008-08 | 2010-11 | 2010-05 |
| NCT00708162 | Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir | COMPLETED | PHASE3 | 2008-07 | 2015-04 | 2010-12 |
| NCT00724711 | Safety and Efficacy Study of Switching From Epzicom to Truvada | COMPLETED | PHASE4 | 2008-07 | 2011-04 | 2011-03 |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | COMPLETED | PHASE1 | 2008-06 | 2012-08 | 2011-12 |
| NCT00712166 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa | COMPLETED | PHASE3 | 2008-05 | 2009-08 | 2009-06 |
| NCT00725803 | Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV | COMPLETED | PHASE2 | 2008-04 | 2009-03 | 2008-10 |
| NCT00617305 | Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) | COMPLETED | PHASE4 | 2008-04 | 2011-07 | 2011-02 |
| NCT00615745 | ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla | COMPLETED | PHASE4 | 2008-04 | 2010-12 | 2010-11 |
| NCT00615810 | ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial | COMPLETED | PHASE4 | 2008-03 | 2010-01 | 2009-10 |
| NCT00713401 | Safety Study of Tecadenoson to Treat Atrial Fibrillation | COMPLETED | PHASE2 | 2008-02 | 2008-07 | 2008-04 |
| NCT00603863 | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer | COMPLETED | PHASE1, PHASE2 | 2008-01 | 2013-12 | 2013-07 |
| NCT00664378 | Efficacy Study of CYT997 in Multiple Myeloma | TERMINATED | PHASE2 | 2008-01 | 2011-02 | 2011-02 |
| NCT00546793 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | COMPLETED | PHASE1, PHASE2 | 2008-01 | 2013-03 | 2013-03 |
| NCT00547066 | Study of Veltuzumab (hA20) at Different Doses in Patients With ITP | TERMINATED | PHASE1, PHASE2 | 2007-11 | 2011-11 | 2011-11 |
| NCT00644332 | An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041) | COMPLETED | PHASE4 | 2007-11 | 2011-01 | 2011-01 |
| NCT00507507 | A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT) | COMPLETED | PHASE2 | 2007-09 | 2012-08 | 2012-02 |
| NCT00507689 | Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant | COMPLETED | PHASE2 | 2007-09 | 2011-05 | 2011-05 |
| NCT00701883 | Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol | COMPLETED | PHASE2 | 2007-08 | 2008-08 | 2008-08 |
| NCT00499967 | Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts | COMPLETED | PHASE1 | 2007-08 | 2009-03 | 2009-02 |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | TERMINATED | PHASE1, PHASE2 | 2007-07 | 2010-10 | 2010-07 |
| NCT00389675 | DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension | TERMINATED | PHASE3 | 2007-05 | 2010-05 | 2010-02 |
| NCT00670657 | CRITIC - Treatment of Candidemia and Invasive Candidiasis | COMPLETED | PHASE4 | 2007-05 | 2009-01 | 2008-12 |
| NCT00421187 | Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics | TERMINATED | PHASE4 | 2007-03 | 2008-05 | 2008-04 |
| NCT00445146 | Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection | COMPLETED | PHASE2 | 2007-02 | 2015-03 | 2015-03 |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | COMPLETED | PHASE1, PHASE2 | 2007-01 | 2009-06 | 2009-06 |
| NCT01845740 | Phase Ib Study of SC Milatuzumab in SLE | COMPLETED | PHASE1 | 2007-01 | 2009-06 | 2009-06 |
| NCT00528957 | Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children | COMPLETED | PHASE3 | 2006-12-28 | 2017-08-16 | 2009-04-06 |
| NCT00362687 | GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance | COMPLETED | PHASE4 | 2006-11 | 2008-10 | 2008-05 |
| NCT00386997 | ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia | TERMINATED | PHASE4 | 2006-11 | 2007-09 | |
| NCT00422487 | Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes | COMPLETED | PHASE2 | 2006-10 | 2007-09 | 2007-08 |
| NCT00389779 | DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension | COMPLETED | PHASE3 | 2006-09 | 2009-08 | 2009-08 |
| NCT00353574 | DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension | TERMINATED | PHASE3 | 2006-09 | 2010-04 | 2010-02 |
| NCT00380068 | Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension | COMPLETED | PHASE3 | 2006-08 | 2009-05 | 2008-07 |
| NCT00365612 | Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients | COMPLETED | PHASE4 | 2006-07 | 2008-01 | 2007-10 |
| NCT00648817 | Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers | COMPLETED | PHASE4 | 2006-07 | 2007-12 | 2007-11 |
| NCT00352053 | Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy | COMPLETED | PHASE3 | 2006-06 | 2013-12 | 2008-09 |
| NCT00330369 | DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension | COMPLETED | PHASE3 | 2006-06 | 2009-01 | 2009-01 |
| NCT00326157 | PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation | COMPLETED | PHASE2 | 2006-06 | 2009-11 | 2009-01 |
| NCT00324649 | Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada | COMPLETED | PHASE4 | 2006-05 | 2008-09 | 2008-03 |
| NCT00353587 | Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin | COMPLETED | PHASE2, PHASE3 | 2006-05 | 2007-11 | 2007-11 |
| NCT00298363 | Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease. | COMPLETED | PHASE2 | 2006-04 | 2011-04 | 2011-04 |
| NCT00307489 | Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil | COMPLETED | PHASE2 | 2006-03 | 2010-10 | 2008-01 |
| NCT00298350 | Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. | COMPLETED | PHASE2 | 2006-02 | 2007-07 | 2007-06 |
| NCT00743340 | Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine | COMPLETED | PHASE2 | 2005-11-22 | 2017-02-13 | 2017-02-13 |
| NCT00224445 | Boosted Atazanavir and Truvada Given Once-Daily - BATON Study | COMPLETED | PHASE4 | 2005-09 | 2007-01 | 2007-01 |
| NCT00323492 | TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada | COMPLETED | PHASE4 | 2005-09 | 2008-03 | 2007-07 |
| NCT00128492 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA) | COMPLETED | PHASE3 | 2005-08 | 2009-01 | 2008-11 |
| NCT00116805 | A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B | COMPLETED | PHASE3 | 2005-06 | 2016-01 | 2007-05 |
| NCT00423592 | Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension | COMPLETED | PHASE2 | 2005-05 | 2009-03 | 2006-01 |
| NCT00112359 | International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa | COMPLETED | PHASE3 | 2005-05 | 2007-04 | 2007-04 |
| NCT00117676 | A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B | COMPLETED | PHASE3 | 2005-02 | 2016-01 | 2007-04 |
| NCT00104520 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa | COMPLETED | PHASE3 | 2005-02 | 2006-09 | 2006-09 |
| NCT00099788 | Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes | COMPLETED | PHASE3 | 2004-10 | 2007-02 | 2007-02 |
| NCT00323544 | SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection | COMPLETED | PHASE3 | 2004-10 | 2007-10 | 2007-06 |
| NCT00106379 | Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients | COMPLETED | PHASE4 | 2004-10 | 2007-01 | |
| NCT00285428 | Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma | COMPLETED | PHASE1, PHASE2 | 2004-09 | 2007-10 | 2007-10 |
| NCT00323687 | SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada | COMPLETED | PHASE4 | 2004-09 | 2007-01 | 2006-10 |
| NCT00224458 | Combination of Efavirenz and Truvada - COMET Study | COMPLETED | PHASE4 | 2004-09 | 2006-02 | |
| NCT00091429 | Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine | COMPLETED | PHASE3 | 2004-08 | 2005-02 | 2005-02 |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | TERMINATED | PHASE2 | 2004-08 | 2006-12 | 2006-12 |
| NCT00597129 | Safety and Efficacy Study of 90Y-hPAM4 at Different Doses | COMPLETED | PHASE1, PHASE2 | 2004-08 | 2007-10 | 2007-10 |
| NCT00095121 | Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B | COMPLETED | PHASE3 | 2004-06 | 2010-04 | 2006-05 |
| NCT00364026 | A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs | COMPLETED | PHASE2 | 2004-06 | 2005-07 | |
| NCT00208312 | ADVANCE MPI 2: Study of Regadenoson Versus AdenoscanĀ® in Patients Undergoing Myocardial Perfusion Imaging (MPI) | COMPLETED | PHASE3 | 2004-04 | 2005-06 | 2005-06 |
| NCT00334412 | COMBISTRAT: AmBisomeĀ® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis | COMPLETED | PHASE4 | 2004-03 | 2006-05 | |
| NCT00596804 | Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | COMPLETED | PHASE1, PHASE2 | 2004-03 | 2007-11 | 2007-11 |
| NCT00578786 | A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) | COMPLETED | PHASE3 | 2004-02 | 2010-03 | 2010-03 |
| NCT00644761 | PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients | COMPLETED | PHASE2 | 2004-02 | 2005-05 | 2005-05 |
| NCT00091598 | ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) | COMPLETED | PHASE3 | 2004-01 | 2006-02 | 2006-02 |
| NCT00423748 | Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. | COMPLETED | PHASE3 | 2003-12 | 2006-02 | |
| NCT00423202 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. | COMPLETED | PHASE3 | 2003-12 | 2005-10 | |
| NCT00362544 | PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisomeĀ® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia | COMPLETED | PHASE4 | 2003-10 | 2006-03 | |
| NCT00208299 | ADVANCE MPI 1: Study of Regadenoson Versus AdenoscanĀ® in Patients Undergoing Myocardial Perfusion Imaging (MPI) | COMPLETED | PHASE3 | 2003-10 | 2006-08 | 2006-08 |
| NCT00077948 | Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure | TERMINATED | PHASE3 | 2003-07 | 2005-06 | 2005-06 |
| NCT00112047 | Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects | COMPLETED | PHASE3 | 2003-07 | 2009-06 | 2005-02 |
| NCT00071201 | Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B | COMPLETED | PHASE3 | 2003-06 | 2006-03 | 2006-03 |
| NCT01055847 | Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection | COMPLETED | PHASE2 | 2003-06 | 2004-09 | 2004-08 |
| NCT00424021 | Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension | COMPLETED | PHASE2 | 2003-04 | 2009-12 | 2009-12 |
| NCT00158730 | Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment | COMPLETED | PHASE3 | 2003-04 | 2005-01 | |
| NCT00324688 | Safety Study of Once a Day ART and Opiate Substitute. | COMPLETED | PHASE4 | 2003-03 | 2006-06 | |
| NCT00643968 | Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial | COMPLETED | PHASE4 | 2003-03 | 2005-09 | 2005-06 |
| NCT00054834 | Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma | TERMINATED | PHASE1 | 2003-03 | | |
| NCT00647946 | Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue | COMPLETED | PHASE2 | 2003-02 | 2006-02 | 2004-10 |
| NCT00645294 | Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV | COMPLETED | PHASE1, PHASE2 | 2003-02 | 2003-08 | 2003-08 |
| NCT00270556 | Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART. | COMPLETED | PHASE2 | 2003-01 | 2004-10 | |
| NCT00642291 | An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects | COMPLETED | PHASE2 | 2002-11 | 2004-07 | 2004-07 |
| NCT00046319 | Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension | COMPLETED | PHASE2 | 2002-09 | 2003-06 | |
| NCT00421395 | Safety Study of NHL With 90Y-hLL2 IgG | COMPLETED | PHASE1, PHASE2 | 2002-08 | 2007-10 | 2007-10 |
| NCT00036634 | A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients | COMPLETED | PHASE1, PHASE2 | 2002-03 | 2003-02 | 2003-02 |
| NCT00051285 | ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure" | TERMINATED | PHASE3 | 2002-02 | 2005-06 | 2005-06 |
| NCT00158704 | Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection. | TERMINATED | NA | 2002-01 | 2005-01 | |
| NCT00016588 | Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs | COMPLETED | NA | 2001-05 | | |
| NCT00011089 | Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations | UNKNOWN | NA | 2001-02 | | |
| NCT00061425 | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG | COMPLETED | PHASE1, PHASE2 | 2000-08 | | 2007-11 |
| NCT00158821 | Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz. | COMPLETED | PHASE3 | 2000-03 | 2013-06 | 2001-12 |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | COMPLETED | PHASE1, PHASE2 | 2000-02 | 2003-06 | |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | COMPLETED | PHASE1, PHASE2 | 2000-01 | 2004-01 | |
| NCT00041639 | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | COMPLETED | PHASE1, PHASE2 | 2000-01 | 2003-12 | |
| NCT00002453 | A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection | COMPLETED | NA | 1999-12 | | |
| NCT00003338 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | UNKNOWN | PHASE2, PHASE3 | 1997-03 | | |
| NCT00003337 | Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma | UNKNOWN | PHASE3 | 1997-03 | | |
| NCT00002234 | Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | COMPLETED | PHASE2 | | | |
| NCT00041691 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery | TERMINATED | PHASE1 | | | |
| NCT00007436 | The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients | UNKNOWN | PHASE3 | | | |
| NCT00002450 | Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients | COMPLETED | PHASE3 | | | |
| NCT00002398 | Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations | COMPLETED | NA | | | |
| NCT00002426 | A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients | COMPLETED | NA | | | |
| NCT00002219 | Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children | UNKNOWN | PHASE2 | | | |
| NCT00002419 | Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment | COMPLETED | PHASE2 | | | |
| NCT00002415 | Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients | COMPLETED | PHASE2 | | | |
| NCT00002396 | The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients | UNKNOWN | PHASE1 | | | |
| NCT00002180 | A Study of PMPA in HIV-Infected Patients | COMPLETED | PHASE1 | | | |
| NCT00002206 | A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs | COMPLETED | PHASE1 | | | |
| NCT00002184 | A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient | COMPLETED | PHASE2 | | | |
| NCT00002379 | The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs | COMPLETED | PHASE2 | | | |
| NCT00002181 | Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS | COMPLETED | NA | | | |
| NCT00002327 | The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients | COMPLETED | PHASE1 | | | |
| NCT00002384 | A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS | UNKNOWN | NA | | | |
| NCT00002161 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3 | COMPLETED | NA | | | |
| NCT00002116 | A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS | COMPLETED | PHASE1 | | | |
| NCT00002115 | A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease. | COMPLETED | PHASE1 | | | |
| NCT00002142 | An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS | COMPLETED | NA | | | |
| NCT00002326 | The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients | COMPLETED | PHASE1 | | | |
| NCT00002346 | The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients | COMPLETED | PHASE1 | | | |
| NCT00002437 | The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS | COMPLETED | PHASE2 | | | |
| NCT00002128 | Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients | COMPLETED | PHASE1 | | | |